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Laparoscopy in Gynecologic Surgery
Keith Terada MD
Laparoscopy has been utilized in gynecologic surgery for over
20 years. With the introduction of video monitoring and the develop
ment of new endoscopic instruments, the role of laparoscopy has
greatly expanded. L.aparoscopy is an in valuable tool in the man
agement of the cancer patient. Current use focuses primarily on the
diagnosis and staging of intraabdominal and pelvic malignancies.
However laparoscopy is also utilized as an adjunct to therapeutic
resection andpalliation. The following is a briefdiscussion of the role
of laparoscopy in the management of gynecologic cancer.
Ovarian Cancer
For cancer of the ovary, laparoscopy is utilized primarily as an
adjunct to diagnosis and staging. It presents an alternative to
laparotomy in the evaluation of the patient with an adnexal mass; if
ovarian cancer is found on laparoscopy, then the surgeon may
proceed immediately with laparotomy and therapeutic resection.
Alternatively, patients with a benign mass or with unresectable
disease can avoid unnecessary laparotomy.
One major concern in the laparoscopic management of the patient
with an adnexal mass is the potential rupture of a malignant ovarian
cyst. Spillage of malignant cells can seed the peritoneal cavity and
theoretically worsen the prognosis. Retrospective studies on this
issue, however, remain equivocal. Most studies demonstrate no
significant difference in survival when intraoperative rupture oc
curs, even if patients receive no postoperative treatment. Other
studies, however, demonstrate a negative impact on survival;4
therefore the issue remains unresolved. The prudent surgeon should
best approach potentially malignant cysts with caution and avoid
intraabdominal spillage if possible.
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Endometrial Cancer
The primary treatment for early stage adenocarcinoma of the
endometrium is hysterectomy and bilateral salpingooophectomy. A
significant number of patients with clinical stage I cancer, however,
may have extrauterine metastasis. The surgical evaluation for en
dometrial cancer, therefore, includes peritoneal washings for
cytology, selective pelvic and paraaortic lymphadenectomy, and
inspection of the peritoneal and serosal surfaces in the abdominal
cavity. Although laparotomy has been the traditional approach for
accomplishing this, recently developed techniques allow all of this
to be performed laparoscopically. Therefore laparoscopic staging,
when combined with vaginal hysterectomy and bilateral
salpingooopherectomy, appears suitable for the treatment of early
stage endometrial cancer.
Padial et. al. reported on a series of patients undergoing
laparoscopic-assisted vaginal hysterectomy (LAVH) compared to
historical controls undergoing abdominal hysterectomy.5Length of
surgery and operative blood loss were similar; length of hospital
stay, post-operative fever, and patient discomfort were lower with
LAVH. Childers6and others78have reported on laparoscopic pelvic
and paraaortic lymphadenectomy. In Childers series operative time
for the paraaortic lymphadenectomy ranged from 20 to 75 minutes,
mean number of lymph nodes harvested was 6.3, mean blood loss
was 50 cc, and there were no major intraoperative complications.
The procedure could not be completed in 3 patients because of
obesity.
Therefore LAVH with laparoscopic lymphadenectomy and stag
ing appears a reasonable alternative to laparotomy in patients with
early stage endometrial cancer. Potential benefits include shorter
hospital stay, less discomfort, and quicker resumption of normal
function. Contraindications include patients with extensive intra
abdominal adhesions and obese patients, in whom laparoscopy and?
or retroperitoneal dissection may not be feasible. Other relative
contraindications include underlying respiratory or cardiovascular
illness. Unknown at this time is whether long-term follow-up will
yield results similar to laparotomy. Areas of concern include the
extent of staging lymphadenectomy, the adequacy of the abdominal
exploration, and the possibility of port site metastasis. Although
LAVH potentially shortens hospital stay and quickens recovery,
overall curability must remain the primary focus and should not be
compromised.
Cervix Cancer
It is recognized that in patients with locally advanced cervix
cancer, approximately 30% will have extrapelvic metastases. This
is of concern, since intraabdominal or retroperitoneal lymph node
metastases clearly impact treatment and outcome. Patients with
paraaortic lymph node metastases require treatment with extended
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field radiation. Ultrasound, CT scan, and lymphangiogram, how
ever, are all of limited sensitivity in detecting metastases. Therefore
pretreatment exploratory laparotomy has been utilized for treat
ment planning. Retroperitoneal lymphadenectomy, however, can
be accomplished utilizing laparoscopic techniques. Advantages
include a quicker recovery and shorter time to initiate definative
treatment. There may also be the advantage of less peritoneal
adhesions and a lower risk of radiation enteritis. Childers et. al.9
reported on 18 patients undergoing laparoscopic staging for cervix
cancer; no significant complications were reported. Therefore
laparoscopy is a potentially useful tool in the pretreatment staging
evaluation of patients with cervix cancer.
Recent reports have also focused on laparosocpy as an adjunct to
therapeutic resection for early stage cervix cancer. Hatch et. al.
reported on 37 patients who underwent laparoscopic assisted radi
cal vaginal hysterectomy for early stage cervix cancer.’° Mean
operative time was significantly longer, however mean hospital
stay was significantly shorter when compared to abdominal radical
hysterectomy. The incidence of bladder, ureteral, and bowel injury
was significantly higher in the laparoscopic group. Survival data
was not reported. This approach to the treatment of stage I cervix
cancer should be considered investigational at this time.
In summary, the role of laparoscopy in the evaluation and manage
ment of the patient with gynecologic cancer is rapidly evolving.
Minimally invasive surgery provides a major advantage for quicker
recovery and less disruption in quality of life. Overall curability,
however, must remain the primary concern and should not be
compromised. Carefully planned prospective studies will be re
quired to examine these various issues.
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